Cancer immunotherapy is, in a word, tantalizing. It might save the life of someone at death’s door and keep the cancer at bay for years. Or it might not work at all. There’s no telling what a patient will experience.
“There’s... Read more »
Many of our devices, from wearables to medical instruments to drones, can capture reams of images. Using algorithms to analyze those images on the devices, in turn, generally takes loads of computing power and energy—sometimes more than is feasible.
AlwaysAI says... Read more »
Five Prime Therapeutics is cutting its headcount by 20 percent, part of a cash-saving effort the company is making to focus on the cancer drugs it has already advanced into clinical trials.
South San Francisco, CA-based Five Prime (NASDAQ: FPRX)... Read more »
Microsoft is making a “wal-to-wal” bet that retailers can harness the Seattle-area tech giant’s products and services to upgrade the brick-and-mortar experience for consumers and patients.
About six months after it struck a partnership with Walmart (NYSE: WMT), Microsoft on... Read more »
The hardware business isn’t cutting it for CyPhy Works, a maker of tethered drones for everything from military uses to disaster response and the oil and gas industry.
Today, the drone company announced a pivot to software—and a rebranding to Aria... Read more »
Smartsheet, a Bellevue, WA-based company that develops collaborative software allowing users to track projects and manage company processes, announced Tuesday it has acquired Seattle-based TernPro, whose flagship product Slope lets customers mark up documents, images, videos, and other media before releasing... Read more »
As Xconomy’s editors looked back at the year just passed, we asked technology leaders to comment on the trends they’d observed in 2018, and the developments they expected in 2019. Some leaders responded with their views on the business impact of... Read more »
[Updated, 11:25 am ET, see below] The partial U.S. government shutdown has just had its first tangible effects on the potential approval of a new drug: The FDA review of a peanut allergy treatment from Aimmune Therapeutics (NASDAQ: AIMT... Read more »